DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Mark Sheptoff Financial Planning LLC

Mark Sheptoff Financial Planning LLC reduced its stake in DexCom, Inc. (NASDAQ:DXCM) by 38.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,990 shares of the medical device company’s stock after selling 1,870 shares during the period. Mark Sheptoff Financial Planning LLC’s holdings in DexCom were worth $233,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Cerity Partners LLC raised its position in DexCom by 190.0% in the third quarter. Cerity Partners LLC now owns 60,050 shares of the medical device company’s stock worth $4,026,000 after acquiring an additional 39,344 shares in the last quarter. Swedbank AB grew its stake in shares of DexCom by 15.2% in the 3rd quarter. Swedbank AB now owns 213,864 shares of the medical device company’s stock worth $14,337,000 after purchasing an additional 28,289 shares during the last quarter. Daiwa Securities Group Inc. raised its holdings in shares of DexCom by 0.6% in the 3rd quarter. Daiwa Securities Group Inc. now owns 77,099 shares of the medical device company’s stock worth $5,169,000 after purchasing an additional 490 shares in the last quarter. Fisher Asset Management LLC lifted its stake in DexCom by 10.6% during the third quarter. Fisher Asset Management LLC now owns 856,124 shares of the medical device company’s stock valued at $57,395,000 after purchasing an additional 82,250 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd bought a new stake in DexCom during the third quarter worth approximately $961,000. 97.75% of the stock is currently owned by institutional investors.

DexCom Stock Down 2.3 %

DXCM opened at $73.55 on Wednesday. The company has a market capitalization of $28.74 billion, a PE ratio of 51.43, a price-to-earnings-growth ratio of 2.30 and a beta of 1.28. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The business has a 50-day moving average of $83.13 and a 200-day moving average of $77.11.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. Equities research analysts forecast that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insider Activity at DexCom

In other DexCom news, CEO Kevin R. Sayer sold 33,359 shares of the firm’s stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the transaction, the chief executive officer now directly owns 319,037 shares in the company, valued at $27,727,505.67. This trade represents a 9.47 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Jacob Steven Leach sold 2,634 shares of the company’s stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $228,920.94. Following the sale, the chief operating officer now owns 268,644 shares of the company’s stock, valued at approximately $23,347,850.04. This trade represents a 0.97 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 105,009 shares of company stock valued at $8,044,178. Insiders own 0.30% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the company. Canaccord Genuity Group increased their price objective on DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a research report on Friday, February 14th. Wells Fargo & Company reiterated an “overweight” rating on shares of DexCom in a research report on Saturday, March 8th. Redburn Atlantic raised DexCom from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $85.00 to $115.00 in a research note on Monday, February 3rd. Cfra Research raised shares of DexCom to a “hold” rating in a research note on Friday, March 21st. Finally, Citigroup lifted their target price on shares of DexCom from $101.00 to $104.00 and gave the stock a “buy” rating in a research report on Tuesday, March 4th. Five investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, DexCom has an average rating of “Moderate Buy” and a consensus price target of $99.82.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.